<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086472</url>
  </required_header>
  <id_info>
    <org_study_id>1654-005</org_study_id>
    <secondary_id>2018-003347-28</secondary_id>
    <secondary_id>MK-1654-002</secondary_id>
    <nct_id>NCT04086472</nct_id>
  </id_info>
  <brief_title>Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of MK-1654 in Healthy Participants (MK-1654-005)</brief_title>
  <official_title>A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if a single intravenous (IV) dose of&#xD;
      MK-1654 when administered at 1 of 4 dose levels results in a reduction in viral load after&#xD;
      intranasal inoculation (with RSV A Memphis 37b) compared to IV placebo. It is hypothesized&#xD;
      that at least 1 of the 4 dose levels of MK-1654 given prior to inoculation will reduce the&#xD;
      area under the viral load-time curve (VL-AUC) from Day 2 through Day 11 (inclusive) after&#xD;
      viral inoculation (Study Day 31 through Day 40) compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Actual">August 14, 2020</completion_date>
  <primary_completion_date type="Actual">March 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Viral Load-time Curve (VL-AUC)</measure>
    <time_frame>10 days; from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40)</time_frame>
    <description>The VL-AUC will be determined by reverse transcription qualitative integrated cycler polymerase chain reaction (RT-qPCR) after viral inoculation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Symptomatic Respiratory Syncytial Virus (RSV) Infection</measure>
    <time_frame>10 days; from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40)</time_frame>
    <description>Symptomatic RSV infection is defined as presence of at least 2 quantifiable RT-qPCR at ≥2 consecutive days, plus symptoms of either any grade from 2 different symptoms from the Subject Symptom Card (SSC) or at least one Grade 2 symptom from ≥1 respiratory categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to 187 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 187 days</time_frame>
    <description>An SAE is any untoward medical occurrence in a clinical study participant that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of MK-1654</measure>
    <time_frame>Predose and Days 1 (1, 2, and 4 hours postdose), 8, 15, 29, 40, and 57</time_frame>
    <description>The post-dosing concentration of MK-1654 will be determined in serum. On Day 1, 3 samples will be taken at 1, 2, and 4 hours after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of RSV Serum Neutralizing Antibody Titers</measure>
    <time_frame>Days 1, 29, 40, and 57</time_frame>
    <description>RSV serum neutralization titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Respiratory Syncytial Viruses</condition>
  <arm_group>
    <arm_group_label>MK-1654 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1654 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1654 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1654 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a single IV infusion of placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-1654</intervention_name>
    <description>Single dose of MK-1654 administered via IV infusion.</description>
    <arm_group_label>MK-1654 100 mg</arm_group_label>
    <arm_group_label>MK-1654 200 mg</arm_group_label>
    <arm_group_label>MK-1654 300 mg</arm_group_label>
    <arm_group_label>MK-1654 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV-A Memphis 37b</intervention_name>
    <description>Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.</description>
    <arm_group_label>MK-1654 100 mg</arm_group_label>
    <arm_group_label>MK-1654 200 mg</arm_group_label>
    <arm_group_label>MK-1654 300 mg</arm_group_label>
    <arm_group_label>MK-1654 900 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is a male or female 18 to 55 years of age in good health with no history of major&#xD;
             medical conditions that will interfere with participant safety, as defined by medical&#xD;
             history, physical examination (including vital signs), electrocardiogram (ECG), and&#xD;
             routine laboratory tests and determined by the Investigator at a screening evaluation.&#xD;
&#xD;
          -  Has a total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m^2 and ≤ 30kg/m^2.&#xD;
&#xD;
          -  If male, agrees to study contraceptive requirements at dosing and continuing until 90&#xD;
             days after dosing or 28 days after viral inoculation (whichever is later) and to not&#xD;
             donate sperm until 90 days after dosing.&#xD;
&#xD;
          -  If female, has a negative pregnancy test at screening and prior to dosing and agrees&#xD;
             to use one form of highly effective contraception if a woman of childbearing potential&#xD;
             (WOCBP), or is not a WOCBP.&#xD;
&#xD;
          -  Has serology results within 90 days of dosing that suggest the participant is&#xD;
             sensitive to RSV infection (i.e., that they are likely to become infected following&#xD;
             inoculation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a female who is breastfeeding or has been pregnant within 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Has a history or evidence of any clinically significant or currently active&#xD;
             cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological,&#xD;
             haematological, hepatic, immunological (including immune suppression), metabolic,&#xD;
             urological, renal, neurological, or psychiatric disease (including participants with a&#xD;
             history of depression and/or anxiety with associated severe psychiatric comorbidities.&#xD;
&#xD;
          -  Has any significant abnormality altering the anatomy of the nose in a substantial way&#xD;
             or nasopharynx that may interfere with the aims of the study and in particular any of&#xD;
             the nasal assessments or viral inoculation (historical nasal polyps can be included,&#xD;
             but large nasal polyps causing current and significant symptoms and/or requiring&#xD;
             regular treatments in the last month will be excluded).&#xD;
&#xD;
          -  Has any clinically significant history of epistaxis (large nosebleeds) within the last&#xD;
             3 months prior to IMP dosing and/or history of being hospitalized due to epistaxis on&#xD;
             any previous occasion.&#xD;
&#xD;
          -  Has a history or currently active symptoms suggestive of upper or lower respiratory&#xD;
             tract infection within 6 weeks prior to dosing.&#xD;
&#xD;
          -  Has any other major disease that, in the opinion of the Investigator, may interfere&#xD;
             with a participant completing the study and necessary investigations.&#xD;
&#xD;
          -  Has a history of anaphylaxis-and/or a history of severe allergic reaction or&#xD;
             significant intolerance to any food or drug, as assessed by the investigator.&#xD;
&#xD;
          -  Has confirmed positive test for drugs of abuse prior to randomization.&#xD;
&#xD;
          -  Has a history or presence of alcohol addiction, or excessive use of alcohol (weekly&#xD;
             intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass&#xD;
             of wine or a measure of spirits), or excessive consumption of xanthine containing&#xD;
             substances (e.g. daily intake in excess of 5 cups of caffeinated drinks e.g. coffee,&#xD;
             tea, cola).&#xD;
&#xD;
          -  Is positive for human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV),&#xD;
             or C (HCV) test.&#xD;
&#xD;
          -  Has evidence of receipt of vaccine within the 4 weeks prior to IMP dosing.&#xD;
&#xD;
          -  Has intention to receive any vaccine(s) before the last day of Follow-up.&#xD;
&#xD;
          -  Receipt of blood or blood products, or loss (including blood donations) of 470 mL or&#xD;
             more of blood during the 3 months prior IMP dosing or planned during the 3 months&#xD;
             after the final visit.&#xD;
&#xD;
          -  Has use within 7 days prior to IMP dosing of any medication or product (prescription&#xD;
             or over-the-counter), for symptoms of hay fever, dermatitis, nasal congestion or&#xD;
             respiratory tract infections including the use of regular nasal or dermal&#xD;
             corticosteroids or antibiotics, apart from those allowed in the study.&#xD;
&#xD;
          -  Has received systemic (intravenous and/or oral) glucocorticoids or systemic antiviral&#xD;
             drugs within 6 months prior to IMP dosing.&#xD;
&#xD;
          -  Has received chronic (defined as more than 14 continuous days) or current&#xD;
             administration of a systemic immunosuppressant or other immune modifying drug,&#xD;
             including any dose of oral corticosteroids, within 6 months prior to dose&#xD;
             administration. The use of topical, inhaled, and nasal glucocorticoids will be&#xD;
             permitted.&#xD;
&#xD;
          -  Has used or anticipated use during the conduct of the study of concomitant medications&#xD;
             (prescription and/or non-prescription), including vitamins or herbal and dietary&#xD;
             supplements within the specified windows (within 7 days prior to IMP dosing), unless&#xD;
             in the opinion of the Principal Investigator, the medication will not interfere with&#xD;
             the study procedures, outcomes, or compromise participant safety.&#xD;
&#xD;
          -  Has a history (participant recall) of receiving any human immunoglobulin preparation&#xD;
&#xD;
          -  Has received any investigational drug within 3 months prior to IMP dosing.&#xD;
&#xD;
          -  Has received ≥3 investigational drugs within the previous 12 months prior to IMP&#xD;
             dosing.&#xD;
&#xD;
          -  Has prior participation in another Human Viral Challenge study with a respiratory&#xD;
             virus of the same virus family in the preceding 3 months taken from the date of viral&#xD;
             challenge in the previous study to the date of expected viral inoculation in this&#xD;
             study.&#xD;
&#xD;
          -  Has prior participation in any RSV related (vaccine, monoclonal antibody or small&#xD;
             molecule) interventional trial.&#xD;
&#xD;
          -  Has a forced expiratory volume in 1 second (FEV1) &lt; 80%.&#xD;
&#xD;
          -  Has presence of fever, defined as participant presenting with a temperature reading of&#xD;
             ≥ 37.9°C on day of IMP dosing.&#xD;
&#xD;
          -  Has smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20&#xD;
             cigarettes a day for 10 years]).&#xD;
&#xD;
          -  Has venous access deemed inadequate for the phlebotomy and demands of the study.&#xD;
&#xD;
          -  Presents any concern by the investigator regarding safe participation in the study or&#xD;
             for any other reason the investigator considers the participant inappropriate for&#xD;
             participation in the study.&#xD;
&#xD;
          -  Has any contraindication for IV infusion.&#xD;
&#xD;
          -  Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or&#xD;
             child) who is investigational site or Sponsor staff directly involved with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HVIVO Services Ltd ( Site 0001)</name>
      <address>
        <city>London</city>
        <zip>E1 2AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <results_first_submitted>March 18, 2021</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT04086472/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult male and female participants were recruited at a single study site in the United Kingdom.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-1654 100 mg</title>
          <description>Participants receive a single intravenous (IV) infusion of MK-1654 100 mg on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MK-1654 200 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MK-1654 300 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MK-1654 900 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants receive a single IV infusion of placebo on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MK-1654 or Placebo</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Inoculated With Respiratory Syncytial Virus (RSV) A Memphis 37b</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Inoculated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-1654 100 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>MK-1654 200 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MK-1654 300 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MK-1654 900 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants receive a single IV infusion of placebo on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="6.9"/>
                    <measurement group_id="B2" value="27.1" spread="8.3"/>
                    <measurement group_id="B3" value="27.6" spread="8.7"/>
                    <measurement group_id="B4" value="26.4" spread="4.5"/>
                    <measurement group_id="B5" value="25.3" spread="4.1"/>
                    <measurement group_id="B6" value="27.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Viral Load-time Curve (VL-AUC)</title>
        <description>The VL-AUC will be determined by reverse transcription qualitative integrated cycler polymerase chain reaction (RT-qPCR) after viral inoculation.</description>
        <time_frame>10 days; from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40)</time_frame>
        <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants receive a single IV infusion of placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Viral Load-time Curve (VL-AUC)</title>
          <description>The VL-AUC will be determined by reverse transcription qualitative integrated cycler polymerase chain reaction (RT-qPCR) after viral inoculation.</description>
          <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available are included.</population>
          <units>log10 copies-/ml*days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.94" lower_limit="12.11" upper_limit="27.78"/>
                    <measurement group_id="O2" value="14.74" lower_limit="6.90" upper_limit="22.58"/>
                    <measurement group_id="O3" value="16.44" lower_limit="8.89" upper_limit="23.99"/>
                    <measurement group_id="O4" value="15.33" lower_limit="7.50" upper_limit="23.17"/>
                    <measurement group_id="O5" value="21.25" lower_limit="13.96" upper_limit="28.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.808</p_value>
            <method>ANOVA</method>
            <param_type>Least squares (LS) Mean Difference</param_type>
            <param_value>-1.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.25</ci_lower_limit>
            <ci_upper_limit>7.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.46</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.58</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.273</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.87</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Symptomatic Respiratory Syncytial Virus (RSV) Infection</title>
        <description>Symptomatic RSV infection is defined as presence of at least 2 quantifiable RT-qPCR at ≥2 consecutive days, plus symptoms of either any grade from 2 different symptoms from the Subject Symptom Card (SSC) or at least one Grade 2 symptom from ≥1 respiratory categories.</description>
        <time_frame>10 days; from Day 2 through Day 11 (inclusive) after viral inoculation (Study Day 31 through Day 40)</time_frame>
        <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants receive a single IV infusion of placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic Respiratory Syncytial Virus (RSV) Infection</title>
          <description>Symptomatic RSV infection is defined as presence of at least 2 quantifiable RT-qPCR at ≥2 consecutive days, plus symptoms of either any grade from 2 different symptoms from the Subject Symptom Card (SSC) or at least one Grade 2 symptom from ≥1 respiratory categories.</description>
          <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.85" lower_limit="25.13" upper_limit="80.78"/>
                    <measurement group_id="O2" value="30.77" lower_limit="9.09" upper_limit="61.43"/>
                    <measurement group_id="O3" value="35.71" lower_limit="12.76" upper_limit="64.86"/>
                    <measurement group_id="O4" value="30.77" lower_limit="9.09" upper_limit="61.43"/>
                    <measurement group_id="O5" value="53.33" lower_limit="26.59" upper_limit="78.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment vs. Placebo</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.57</ci_lower_limit>
            <ci_upper_limit>37.78</ci_upper_limit>
            <estimate_desc>95% CI based on the Chan and Zhang exact method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment vs. Placebo</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-22.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.70</ci_lower_limit>
            <ci_upper_limit>15.53</ci_upper_limit>
            <estimate_desc>95% CI based on the Chan and Zhang exact method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment vs. Placebo</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-17.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.09</ci_lower_limit>
            <ci_upper_limit>20.01</ci_upper_limit>
            <estimate_desc>95% CI based on the Chan and Zhang exact method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment vs. Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment vs. Placebo</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-22.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.70</ci_lower_limit>
            <ci_upper_limit>15.53</ci_upper_limit>
            <estimate_desc>95% CI based on the Chan and Zhang exact method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Adverse Event (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
        <time_frame>Up to 187 days</time_frame>
        <population>All participants who received any study intervention are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants receive a single IV infusion of placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
          <population>All participants who received any study intervention are included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Serious Adverse Event (SAE)</title>
        <description>An SAE is any untoward medical occurrence in a clinical study participant that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.</description>
        <time_frame>Up to 187 days</time_frame>
        <population>All participants who received any study intervention are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants receive a single IV infusion of placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Serious Adverse Event (SAE)</title>
          <description>An SAE is any untoward medical occurrence in a clinical study participant that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.</description>
          <population>All participants who received any study intervention are included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of MK-1654</title>
        <description>The post-dosing concentration of MK-1654 will be determined in serum. On Day 1, 3 samples will be taken at 1, 2, and 4 hours after administration.</description>
        <time_frame>Predose and Days 1 (1, 2, and 4 hours postdose), 8, 15, 29, 40, and 57</time_frame>
        <population>All randomized participants who received MK-1654 and had no major protocol deviations are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of MK-1654</title>
          <description>The post-dosing concentration of MK-1654 will be determined in serum. On Day 1, 3 samples will be taken at 1, 2, and 4 hours after administration.</description>
          <population>All randomized participants who received MK-1654 and had no major protocol deviations are included.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0369" spread="0.148"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="3.13"/>
                    <measurement group_id="O2" value="36.0" spread="6.65"/>
                    <measurement group_id="O3" value="62.6" spread="16.8"/>
                    <measurement group_id="O4" value="134" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="6.42"/>
                    <measurement group_id="O2" value="72.6" spread="12.5"/>
                    <measurement group_id="O3" value="125" spread="25.7"/>
                    <measurement group_id="O4" value="298" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="6.19"/>
                    <measurement group_id="O2" value="68.8" spread="11.5"/>
                    <measurement group_id="O3" value="122" spread="26.9"/>
                    <measurement group_id="O4" value="287" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="2.54"/>
                    <measurement group_id="O2" value="33.0" spread="5.48"/>
                    <measurement group_id="O3" value="56.7" spread="12.8"/>
                    <measurement group_id="O4" value="140" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="2.49"/>
                    <measurement group_id="O2" value="29.1" spread="4.19"/>
                    <measurement group_id="O3" value="47.6" spread="8.57"/>
                    <measurement group_id="O4" value="123" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="2.11"/>
                    <measurement group_id="O2" value="23.1" spread="3.06"/>
                    <measurement group_id="O3" value="38.5" spread="6.99"/>
                    <measurement group_id="O4" value="103" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.74"/>
                    <measurement group_id="O2" value="21.4" spread="3.18"/>
                    <measurement group_id="O3" value="35.6" spread="7.16"/>
                    <measurement group_id="O4" value="88.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" spread="2.01"/>
                    <measurement group_id="O2" value="18.7" spread="2.60"/>
                    <measurement group_id="O3" value="32.3" spread="6.14"/>
                    <measurement group_id="O4" value="79.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of RSV Serum Neutralizing Antibody Titers</title>
        <description>RSV serum neutralization titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Days 1, 29, 40, and 57</time_frame>
        <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available for the time point are included.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1654 100 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MK-1654 200 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MK-1654 300 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MK-1654 900 mg</title>
            <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants receive a single IV infusion of placebo on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of RSV Serum Neutralizing Antibody Titers</title>
          <description>RSV serum neutralization titers were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>All randomized participants who received a dose of study drug, a RSV inoculation, and had data available for the time point are included.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669.1" lower_limit="487.5" upper_limit="918.4"/>
                    <measurement group_id="O2" value="699.3" lower_limit="530.9" upper_limit="921.0"/>
                    <measurement group_id="O3" value="954.0" lower_limit="606.1" upper_limit="1501.4"/>
                    <measurement group_id="O4" value="893.8" lower_limit="649.0" upper_limit="1230.8"/>
                    <measurement group_id="O5" value="837.4" lower_limit="567.9" upper_limit="1234.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11137.6" lower_limit="8884.8" upper_limit="13961.7"/>
                    <measurement group_id="O2" value="24836.1" lower_limit="21971.4" upper_limit="28074.3"/>
                    <measurement group_id="O3" value="41544.8" lower_limit="33688.4" upper_limit="51233.3"/>
                    <measurement group_id="O4" value="100163.5" lower_limit="84649.3" upper_limit="118521.1"/>
                    <measurement group_id="O5" value="1225.4" lower_limit="621.0" upper_limit="2418.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4727.2" lower_limit="4026.3" upper_limit="5550.0"/>
                    <measurement group_id="O2" value="8135.8" lower_limit="6945.6" upper_limit="9530.0"/>
                    <measurement group_id="O3" value="13263.2" lower_limit="11050.6" upper_limit="15918.9"/>
                    <measurement group_id="O4" value="31367.8" lower_limit="26876.0" upper_limit="36610.3"/>
                    <measurement group_id="O5" value="1037.1" lower_limit="673.9" upper_limit="1596.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4517.1" lower_limit="3899.6" upper_limit="5232.2"/>
                    <measurement group_id="O2" value="8357.6" lower_limit="7073.1" upper_limit="9875.4"/>
                    <measurement group_id="O3" value="13510.9" lower_limit="11564.1" upper_limit="15785.4"/>
                    <measurement group_id="O4" value="27935.5" lower_limit="19429.8" upper_limit="40164.6"/>
                    <measurement group_id="O5" value="1540.4" lower_limit="1025.9" upper_limit="2313.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4377.8" lower_limit="3338.4" upper_limit="5740.9"/>
                    <measurement group_id="O2" value="5531.9" lower_limit="4315.0" upper_limit="7092.1"/>
                    <measurement group_id="O3" value="11557.9" lower_limit="9428.4" upper_limit="14168.4"/>
                    <measurement group_id="O4" value="22209.6" lower_limit="17585.6" upper_limit="28049.5"/>
                    <measurement group_id="O5" value="1500.2" lower_limit="908.7" upper_limit="2476.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 187 days</time_frame>
      <desc>All participants who received a dose of any study intervention are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-1654 100 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 100 mg on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>MK-1654 200 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 200 mg on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MK-1654 300 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 300 mg on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MK-1654 900 mg</title>
          <description>Participants receive a single IV infusion of MK-1654 900 mg on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants receive a single IV infusion of placebo on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>SARS-CoV-2 test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

